Mesoporous carbon as a carrier for celecoxib: The improved inhibition effect on MDA-MB-231 cells migration and invasion

Asian Journal of Pharmaceutical Sciences

Volumn 9, Issue 2, 2014, Pages 82-91

  Zhu, Wenquan ^a   Zhao, Qinfu ^a   Zheng, Xin ^a   Zhang, Zhiwen ^b   Jiang, Tongying ^a   Li, Yaping ^b   Wang, Siling ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Carrier; Dissolution; Invasion; Mesoporous carbon; Migration

Indexed keywords

CARBON; CELECOXIB; DRUG CARRIER; MESOPOROUS CARBON; UNCLASSIFIED DRUG;

ABSORPTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG RELEASE; DRUG SOLUBILITY; EVAPORATION; HUMAN; HUMAN CELL; SOLID STATE; WOUND HEALING;

EID: 84926004397     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2014.02.001     Document Type: Article

References (33)

1. Trenis D.P., William J.A., John D.L. Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev 2011, 63:568-581.
2. Sharon M., Geoffrey L. Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. Adv Drug Deliv Rev 2009, 61:381-387.
3. Jong L.R., Myung W.S., Seok W.P., et al. Celecoxib can prevent tumor growth and distant metastasis in postoperative setting. Cancer Res 2004, 64:3230-3235.
4. Wei H.S., Guo S.C., Xi L.O., et al. Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor γ synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett 2009, 275:247-255.
5. Wei A.Y., Wang L.W., He Y.J., et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004, 64:2030-2038.
6. Masashige T., Masakazu Y., Kazunori N., et al. A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells. Cancer Lett 2006, 244:247-251.
7. Shi H.Y., Lv F.J., Zhu S.T., et al. Dual inhibition of 5-LOX and COX-2 suppresses esophageal squamous cell carcinoma. Cancer Lett 2011, 309:19-26.
8. Sokbom K., Moon H.K., In A.P., et al. Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix. Cancer Lett 2006, 237:305-311.
9. Natesan S., Subhabrata R., Saroj K.G., et al. Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull 2004, 27:1993-1999.
10. Faiyaz S., Sanjula B., Alka A., et al. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. J Nanobiotech 2008, 6:1-8.
11. Michael M., Corey B., Ron B., et al. Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low solubility, high-permeability drug. Pharm Res 2012, 29:427-440.
12. Cao X., Deng W.W., Fu M., et al. Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: Invitro release kinetics and invitro/invivo correlations in beagle dogs. Eur J Pharm Sci 2013, 48:64-71.
13. Hu Y.C., Zhi Z.Z., Wang T.Y., et al. Incorporation of indomethacin nanoparticles into 3-D ordered macroporous silica for enhanced dissolution and reduced gastric irritancy. Eur J Pharm Biopharm 2011, 79:544-551.
14. Hu Y.C., Zhi Z.Z., Jiang T.Y., et al. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J Control Release 2010, 145:257-263.
15. Sang J.S., Bai X., Sang B.L. Inorganic hollow nanoparticles and nanotubes in Nanomedicine: part 1. Drug/gene delivery applications. Drug Discov Today 2007, 12:650-656.
16. Sang J.S., Bai X., Sang B.L. Inorganic hollow nanoparticles and nanotubes in Nanomedicine: part 2: Imaging, diagnostic, and therapeutic applications. Drug Discov Today 2007, 12:657-663.
17. Wang X.F., Liu P., Tian Y. Ordered mesoporous carbons for ibuprofen drug loading and release behavior. Micropor Mesopor Mat 2011, 142:334-340.
18. Zhao P., Wang L.H., Sun C.S., et al. Uniform mesoporous carbon as a carrier for poorly water soluble drug and its cytotoxicity study. Eur J Pharm Biopharm 2012, 80:535-543.
19. Ji S.I., Byong C.B., Young-Seak L. The effect of carbon nanotubes on drug delivery in an electro-sensitive transdermal drug delivery system. Biomaterials 2010, 31:1414-1419.
20. Zhao P., Jiang H.T., Jiang T.Y., et al. Inclusion of celecoxib into fibrous ordered mesoporous carbon for enhanced oral bioavailability and reduced gastric irritancy. Eur J Pharm Sci 2012, 45:639-647.
21. Zhu W.Q., Wan L., Zhang C., et al. Exploitation of 3D face-centered cubic mesoporous silica as a carrier for a poorly water soluble drug: influence of pore size on release rate. Mat Sci Eng C 2014, 34:78-85.
22. Le J.J., Jing Y.S., Zhen Y.L., et al. Invitro and invivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes. Int J Pharm 2013, 445:12-19.
23. Shyamal K.D., Shobhna K., Hirotoshi Y., et al. Effects of surface acidity and pore size of mesoporous alumina on degree of loading and controlled release of ibuprofen. Micropor Mesopor Mat 2009, 118:267-272.
24. Shobhna K., Rajesh H., Aninda J.B. Influence of surface chemistry of mesoporous alumina with wide pore distribution on controlled drug release. J Control Release 2009, 140:34-39.
25. Salonen J., Laitinen L., Kaukonen A.M., et al. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J Control Release 2005, 108:362-374.
26. Zhang Y.Z., Zhang J.H., Jiang T.Y., et al. Inclusion of the poorly water-soluble drug simvastatin in mesocellular foam nanoparticles: drug loading and release properties. Int J Pharm 2011, 410:118-124.
27. Zhang Y.Z., Jiang T.Y., Zhang Q., et al. Inclusion of telmisartan in mesocellular foam nanoparticles: drug loading and release property. Eur J Pharm Biopharm 2010, 76:17-23.
28. Xiao H.P., Thomas J., Larry A. Increasing the dissolution rate of a low-solubility drug through a crystalline-amorphous transition: a case study with indomethicin. Drug Dev Ind Pharm 2008, 34:221-231.
29. Abhik B., Yong Z., Michael L.C., et al. A soluble transforming growth factor β type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res 1999, 59:5041-5046.
30. Yuka F., Yasunori I., Shu J.N., et al. Lipid nanoparticles with no surfactant improve oral absorption rate of poorly water-soluble drug. Int J Pharm 2013, 451:92-94.
31. Sandeep K.V., Dan Z., Giorgia P., et al. Delivery of drugs and biomolecules using carbon nanotubes. Carbon 2011, 49:4077-4097.
32. Ruibin L., Ren A.W., Liang Z., et al. Folate and iron difunctionalized multiwall carbon nanotubes as dual-targeted drug nanocarrier to cancer cells. Carbon 2011, 49:1797-1805.
33. Elena H., Vera N., Constanze L., et al. Drug loading, dispersion stability, and therapeutic efficacy in targeted drug delivery with carbon nanotubes. Carbon 2012, 50:622-632.